General Biotechnology

The real patent is the weak one nobody challenged.
That line hits like a reminder that the most expensive battles in pharma arent always fought on the battlefield everyones watching.
For years, the industry narrative around patent thickets has been fra…

Drug patent wars arent won in courttheyre won in the archive.
If youve watched (or worked on) drug patent litigation, youve probably noticed a pattern: the loudest legal firepower doesnt always translate into the fastest wins. What consistently separat…

The quiet strategy that can beat a patent cliff isnt always a lawsuitits timing.
For years, patent cliff talk has sounded like a countdown clock: the last day a brand has market exclusivity, then generic entry arrives and margins evaporate.
But the rea…

Most pharma portfolios dont have a patent problem. They have a timing problem.
The gap between a genuinely defensible, litigation-ready drug patent and a later, already-listed patent can be wider than many companiesespecially those that model value usi…

One Day Late. Nine Figures Short. What First to File Really Costs.
If you ever needed a reminder that patent law is less about inspiration and more about timing, look no further than the cautionary tale at the heart of first to file.
In pharmaand e…

🚨 Most skinny label opportunities dont look like opportunitiesuntil its too late.
Heres the problem: by the time the market notices a filers paragraph IV strategy (and the litigation headlines start flying), the real winners have already positioned …

Pharma strategy has a blind spot: many teams still treat 180-day exclusivity like a finish linewhen its really a starting pistol.
DrugPatentWatchs piece on the first filers trap lands on a hard truth for generic and biosimilar players: winning the lega…

Pharma has a new winning strategyand its deceptively simple: spend less up front, file less, and still expect outsized returns.
But the premise hides a trap.
In a market where blockbuster economics keep getting compressed, companies are increasingly op…

Most patent cases arent won in court. Theyre won in the gap between filing and enforcement.
Thats the hidden ROI in challenging a weak method-of-use patent earlybefore it becomes a habitual pay-to-delay lever in the background of the drug launch calend…

The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
In generic drug litigation, everyone loves a headline: First-to-file gets 180 days of exclusivity.
It sounds like a guaranteed payday. File first, stand in the golden lane, an…